1800-272-662
Shopping Cart 0
countryflagAU
Login

Ginkgo Bioworks Holdings

Healthcare US DNA

6.84USD
0.50(7.89%)

Last update at 2026-03-11T14:53:00Z

Day Range

6.316.86
LowHigh

52 Week Range

1.122.54
LowHigh

Fundamentals

  • Previous Close 6.34
  • Market Cap3728.44M
  • Volume380926
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-709.51802M
  • Revenue TTM314.98M
  • Revenue Per Share TTM0.17
  • Gross Profit TTM 273.49M
  • Diluted EPS TTM-0.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -2121.39900M -1838.12200M -124.83400M -119.83500M
Minority interest 1.44M -6.59500M 8.68M 8.79M
Net income -2106.37200M -1836.64200M -126.72300M -119.85700M
Selling general administrative 1429.80M 862.95M 38.31M 29.48M
Selling and marketing expenses - - - -
Gross profit 273.49M 184.15M 61.05M 54.18M
Reconciled depreciation 44.42M 29.08M 13.86M 10.76M
Ebit -2208.95200M -1828.46700M -137.02700M -71.59800M
Ebitda -2180.39400M -1877.57100M -107.51500M -81.04600M
Depreciation and amortization 28.56M -49.10400M 29.51M -9.44800M
Non operating income net other 87.55M - - -
Operating income -2208.95200M -1828.46700M -137.02700M -71.59800M
Other operating expenses 2686.66M 2142.30M 213.68M 125.78M
Interest expense 0.11M 2.37M 2.38M 2.42M
Tax provision -15.02700M -1.48000M 1.89M 0.02M
Interest income 20.26M 0.84M 2.58M 5.76M
Net interest income 20.16M -1.53600M 0.20M 3.33M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -15.02700M -1.48000M 1.89M 0.02M
Total revenue 477.71M 313.84M 76.66M 54.18M
Total operating expenses 2482.44M 2012.61M 198.07M 125.78M
Cost of revenue 204.22M 129.69M 15.61M 0.00000M
Total other income expense net 87.55M -9.65500M 12.19M -48.23700M
Discontinued operations - - - -
Net income from continuing ops -2106.37200M -1836.64200M -126.72300M -119.85700M
Net income applicable to common shares -2104.92900M -1830.04700M -126.60900M -119.32700M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2539.32M 2070.99M 675.15M 697.32M
Intangible assets 111.04M 21.64M 3.29M 3.84M
Earning assets - - - -
Other current assets 49.02M 0.70M 1.44M 5.30M
Total liab 803.04M 503.61M 205.10M 204.25M
Total stockholder equity 1736.28M 1505.37M 461.38M 493.06M
Deferred long term liab 174.77M 174.74M - -
Other current liab 114.69M 92.58M 30.02M 23.44M
Common stock 0.19M 0.16M 0.13M 0.08M
Capital stock 0.19M 0.16M 0.13M -
Retained earnings -4397.65900M -2297.92500M -467.87800M -341.26900M
Other liab 216.83M 346.57M 115.36M 138.62M
Good will 60.21M 21.31M 1.86M 1.86M
Other assets 88.72M 43.99M 18.90M 9.31M
Cash 1315.79M 1550.00M 380.80M -
Cash and equivalents 1315.79M 1550.00M 380.80M 495.29M
Total current liabilities 172.96M 134.76M 73.22M 40.07M
Current deferred revenue 47.82M 33.24M 28.82M -
Net debt -902.53600M -1526.97400M -363.79800M -
Short term debt 29.33M 0.75M 0.48M 0.00000M
Short long term debt - - - -
Short long term debt total 413.26M 23.03M 17.00M -
Other stockholder equity 6133.75M 3804.84M 929.12M -
Property plant equipment 715.53M 145.77M 121.44M 63.13M
Total current assets 1450.08M 1723.05M 426.54M 511.93M
Long term investments 113.73M 102.04M 103.12M -
Net tangible assets 1565.03M 1462.41M 456.04M 487.19M
Short term investments - - - -
Net receivables 80.91M 149.90M 24.17M 8.78M
Long term debt - - - -
Inventory 4.36M 3.36M 2.74M 0.00000M
Accounts payable 10.45M 8.19M 13.89M 2.44M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - 62.01M - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -2.63200M -1.71500M - -
Additional paid in capital - - - -
Common stock total equity 0.19M 0.16M - -
Preferred stock total equity - - - -
Retained earnings total equity -4397.65900M -2297.92500M - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 202.46M 43.99M 5.60M -
Deferred long term asset charges - - - -
Non current assets total 1089.24M 347.94M 248.61M -
Capital lease obligations 413.26M 23.03M 17.00M -
Long term debt total 0.00000M 22.28M 16.52M 16.77M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -67.39400M -5.00000M -67.12100M -50.13300M
Change to liabilities -50.45200M -12.74500M -12.40400M 5.55M
Total cashflows from investing activities -67.39400M -73.25700M -67.12100M -74.60200M
Net borrowings 97.84M -1.12300M -0.74800M 198.60M
Total cash from financing activities 95.34M 1534.14M 90.32M 410.38M
Change to operating activities -44.93300M 65.93M 2.85M 6.87M
Net income -2106.37200M -1836.64200M -126.72300M -119.85700M
Change in cash -223.34700M 1207.05M -112.63300M 291.12M
Begin period cash flow 1592.93M 385.88M 498.51M 207.39M
End period cash flow 1369.58M 1592.93M 385.88M 498.51M
Total cash from operating activities -252.19800M -253.81800M -135.83000M -44.66300M
Issuance of capital stock 99.30M 0.00000M 91.04M 212.18M
Depreciation 44.42M 29.08M 13.86M 10.76M
Other cashflows from investing activities -15.12300M -16.73600M -9.30000M -52.38300M
Dividends paid - - - -
Change to inventory 0.16M -0.62600M -2.73600M -2.22200M
Change to account receivables 55.02M -114.09400M -14.22800M -1.84300M
Sale purchase of stock 99.54M -24.99800M 91.07M -0.40800M
Other cashflows from financing activities -2.72900M 1560.27M 91.07M 411.62M
Change to netincome 1859.54M 1608.69M 3.43M 53.33M
Capital expenditures 52.27M 56.52M 57.82M 22.22M
Change receivables 55.02M -114.09400M - -
Cash flows other operating -58.80900M -34.69500M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -224.25500M 1207.07M - -
Change in working capital -37.00600M -61.53700M -26.51500M 10.58M
Stock based compensation 1930.64M 1606.02M 0.48M 0.77M
Other non cash items -69.27500M -20.94700M -1.06100M -1.64200M
Free cash flow -304.46900M -310.33900M -193.65100M -66.88200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DNA
Ginkgo Bioworks Holdings		 0.50 7.89% 6.84 - - 11.43 2.88 9.38 -4.4915
NVO
Novo Nordisk A/S		 0.16 0.41% 38.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.89 0.98% 494.28 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 3.71 0.48% 775.75 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings

27 Drydock Avenue, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Dr. Jason Kelly Founder, CEO & Director 1981
Dr. Reshma P. Shetty Founder, Pres, COO & Director 1981
Mr. Mark E. Dmytruk Chief Financial Officer 1971
Mr. Thomas Knight Jr. Founder NA
Mr. Austin Che Founder, Head of Strategy & Treasurer NA
Mr. Bartholomew Canton Founder, CTO & Sec. NA
Marie E Fallon Chief Accounting Officer NA
Karen Tepichin Gen. Counsel & Sec. NA
Ms. Anna Marie Wagner Sr. VP of Corp. Devel. NA
Ms. Samantha Sutton Head of People NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.